247 related articles for article (PubMed ID: 26529238)
1. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
[TBL] [Abstract][Full Text] [Related]
2. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
[TBL] [Abstract][Full Text] [Related]
3. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
[TBL] [Abstract][Full Text] [Related]
7. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
[TBL] [Abstract][Full Text] [Related]
9. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
10. A 2-Dose AERAS-402 Regimen Boosts CD8
Sivakumaran D; Blatner G; Bakken R; Hokey D; Ritz C; Jenum S; Grewal HMS
Front Immunol; 2021; 12():673532. PubMed ID: 34177914
[TBL] [Abstract][Full Text] [Related]
11. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Tameris M; Geldenhuys H; Luabeya AK; Smit E; Hughes JE; Vermaak S; Hanekom WA; Hatherill M; Mahomed H; McShane H; Scriba TJ
PLoS One; 2014; 9(2):e87340. PubMed ID: 24498312
[TBL] [Abstract][Full Text] [Related]
12. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.
Hoft DF; Blazevic A; Stanley J; Landry B; Sizemore D; Kpamegan E; Gearhart J; Scott A; Kik S; Pau MG; Goudsmit J; McClain JB; Sadoff J
Vaccine; 2012 Mar; 30(12):2098-108. PubMed ID: 22296955
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
Rowland R; Pathan AA; Satti I; Poulton ID; Matsumiya MM; Whittaker M; Minassian AM; O'Hara GA; Hamill M; Scott JT; Harris SA; Poyntz HC; Bateman C; Meyer J; Williams N; Gilbert SC; Lawrie AM; Hill AV; McShane H
Hum Vaccin Immunother; 2013 Jan; 9(1):50-62. PubMed ID: 23143773
[TBL] [Abstract][Full Text] [Related]
15. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H
Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906
[TBL] [Abstract][Full Text] [Related]
16. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Wajja A; Kizito D; Nassanga B; Nalwoga A; Kabagenyi J; Kimuda S; Galiwango R; Mutonyi G; Vermaak S; Satti I; Verweij J; Tukahebwa E; Cose S; Levin J; Kaleebu P; Elliott AM; McShane H
PLoS Negl Trop Dis; 2017 May; 11(5):e0005440. PubMed ID: 28472067
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Whelan KT; Pathan AA; Sander CR; Fletcher HA; Poulton I; Alder NC; Hill AV; McShane H
PLoS One; 2009 Jun; 4(6):e5934. PubMed ID: 19529780
[TBL] [Abstract][Full Text] [Related]
19. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H
Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508
[TBL] [Abstract][Full Text] [Related]
20. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.
Darrah PA; Bolton DL; Lackner AA; Kaushal D; Aye PP; Mehra S; Blanchard JL; Didier PJ; Roy CJ; Rao SS; Hokey DA; Scanga CA; Sizemore DR; Sadoff JC; Roederer M; Seder RA
J Immunol; 2014 Aug; 193(4):1799-811. PubMed ID: 25024382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]